OnCore Login

Return to Trial Database

GI05-102

Phase I / Randomized Phase II Study of Second Line Therapy With Irinotecan and Cetuximab With or Without RAD001, an Oral mTOR Inhibitor for Patients With Metastatic Colorectal Cancer: Hoosier Oncology Group GI05-102

Status

Study Completed

Cancer Type(s)

Colorectal

Study Contact

Publications

Phase I/II study of everolimus (E) with irinotecan (Iri) and cetuximab (C) in 2nd line metastatic colorectal cancer (mCRC)
  • EG Chiorean, J Picus, T Breen, RH Ansari, WA Harb, M Burns, AJ Spittler, PJ Loehrer
Phase I study of everolimus (RAD001) with Irinotecan (Iri) and Cetuximab (C) in 2nd line metastatic colorectal cancer (mCRC)
  • S Shadha, M Yu, J Picus, J Bufill, W Harb, M Burns, J Spittler, J Flynn, Y Zeng, G Vance, C Currie, J Wu, PJ Loehrer, EG Chiorean

Trial Locations

All sites in which the trial GI05-102 being conducted in.
No data was found
  • 7676 Interactive Way, Suite 120, Indianapolis, IN 46278